AIAISci
中文
clinical trialBiotech

Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care

Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care (NCT06832722)

updatedDate Venue ClinicalTrials.gov

Source-permitted summary

Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care | Phase: PHASE1 | Conditions: Shock, Cardiogenic

SourceClinicalTrials.gov

Verified by AISci

Public source attached

Source status for this paper in the current AISci reviewed snapshot.

Primary source
ClinicalTrials.gov
Correction status
none
Evidence coverage
1 sources / 1 publishers
Last metadata check
Jul 19, 2026
CLINICALTRIALS.GOV: NCT06832722
Open primary source

AI Reading Notes

Core signal

Structured notes generated from source-linked AISci metadata. Treat them as a reading aid, not a substitute for the paper.

Core signal
Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care | Phase: PHASE1 | Conditions: Shock, Cardiogenic
Field context
Clinical and Regulatory
People and labs
Not stated in the reviewed source.
Why it matters
Clinical trial registry updates are translation signals, not commercialization claims by themselves.
Limits to check
ClinicalTrials.gov status does not prove product approval, licensing, revenue, or market adoption.

Publication facts

Type
clinical trialSourceClinicalTrials.gov
Venue
ClinicalTrials.govSourceClinicalTrials.gov

External IDs

Author order

No reviewed author edge is attached to this output.

Organizations

No source-confirmed author affiliation is attached.

Related events

Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care

Topics

Clinical and Regulatory

Relationship evidence

Timeline

  2. clinical trialInvobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care
    SourceClinicalTrials.gov